Schering-Plough's Saphris Hits FDA Roadblock With "Complete Response"
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says there is no need for additional clinical trials for the atypical antipsychotic.
You may also be interested in...
Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review
Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.
Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review
Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.
Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July
FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.